Research programme: ion channel modulators - Xention

Drug Profile

Research programme: ion channel modulators - Xention

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Xention
  • Developer Axxam; Xention
  • Class Small molecules
  • Mechanism of Action Ion channel modulators; Kv1.3 potassium channel inhibitors; ORAI1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Autoimmune disorders; Conduction disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Autoimmune-disorders in United Kingdom (PO)
  • 16 Jul 2016 No recent reports of development identified for research development in Conduction-disorders in United Kingdom
  • 15 Sep 2010 Early research in Conduction disorders in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top